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Abstract 
Postnatal administration of phencyclidine (PCP) in rodents causes major disturbances to neurological 
processes resulting in severe modifications to normal behavioral traits into adulthood. It is routinely used 
to model psychiatric disorders such as schizophrenia, producing many of the dysfunctional processes in 
the brain that are present in this devastating disorder, including elevated levels of apoptosis during 
neurodevelopment and disruptions to myelin and plasticity processes. Lingo-1 (or Leucine-rich repeat and 
immunoglobulin domain-containing protein) is responsible for negatively regulating neurite outgrowth and 
the myelination of axons. Recent findings using a postmortem human brain cohort showed that Lingo-1 
signaling partners in the Nogo receptor (NgR)/p75/TNF receptor orphan Y (TROY) signaling complex, and 
downstream signaling partners With No Lysine (K) (WNK1) and Myelin transcription factor 1 (Myt1), play a 
significant part in schizophrenia pathophysiology. Here we have examined the implication of Lingo-1 and 
its signaling partners in a neurodevelopmental model of schizophrenia using PCP to determine if these 
pathways are altered in the hippocampus throughout different stages of neurodevelopment. Male 
Sprague-Dawley rats were injected subcutaneously with PCP (10 mg/kg) or saline solution on postnatal 
days (PN) 7, 9, and 11. Rats (n = 6/group) were sacrificed at PN12, 5 weeks, or 14 weeks. Relative 
expression levels of Lingo-1 signaling proteins were examined in the hippocampus of the treated rats. 
p75 and Myt1 were decreased (0.001 ≤ p ≤ 0.011) in the PCP treated rats at PN12. There were no 
significant changes in any of the tested proteins at 5 weeks (p > 0.05). At 14 weeks, p75, TROY, and Myt1 
were increased in the PCP treated rats (0.014 ≤ p ≤ 0.022). This is the first report of an alteration in 
Lingo-1 signaling proteins in the rat hippocampus, both directly after PCP treatment in early development 
and in adulthood. Based on our results, we propose that components of the Lingo-1 signaling pathways 
may be involved in the acute neurotoxicity induced by perinatal administration of PCP in rats early in 
development and suggest that this may have implications for the hippocampal deficits seen in 
schizophrenia. 
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Abstract 
 
Postnatal administration of phencyclidine (PCP) in rodents causes major disturbances to 
neurological processes resulting in severe modifications to normal behavioural traits into 
adulthood. It is routinely used to model psychiatric disorders such as schizophrenia, 
producing many of the dysfunctional processes in the brain that are present in this devastating 
disorder; including elevated levels of apoptosis during neurodevelopment, and disruptions to 
myelin and plasticity processes. Lingo-1 (or Leucine-rich repeat and immunoglobulin 
domain-containing protein), is responsible for negatively regulating neurite outgrowth and 
the myelination of axons. Recent findings using a postmortem human brain cohort showed 
that Lingo-1 signaling partners in the Nogo receptor (NgR)/p75/TNF receptor orphan Y 
(TROY) signaling complex, and downstream signaling partners With No Lysine (K) (WNK1) 
and Myelin transcription factor 1 (Myt1), play a significant part in schizophrenia 
pathophysiology. Here we have examined the implication of Lingo-1 and its signaling 
partners in a neurodevelopmental model of schizophrenia using PCP to determine if these 
pathways are altered in the hippocampus throughout different stages of neurodevelopment. 
Male Sprague Dawley rats were injected subcutaneously with PCP (10mg/kg) or saline 
solution on postnatal days (PN)7, 9 and 11. Rats (n=6/group) were sacrificed at PN12, 5 
weeks or 14 weeks. Relative expression levels of Lingo-1 signaling proteins were examined 
in the hippocampus of the treated rats. p75 and Myt1 were decreased (0.001≤p≤0.011) in the 
PCP treated rats at PN12. There were no significant changes in any of the tested proteins at 5 
weeks (p>0.05). At 14 weeks, p75, TROY, and Myt1 were increased in the PCP treated rats 
(0.014≤p≤0.022). This is the first report of an alteration in Lingo-1 signaling proteins in the 
rat hippocampus; both directly after PCP treatment in early development, and in adulthood. 
Based on our results we propose that components of the Lingo-1 signaling pathways may be 
involved in the acute neurotoxicity induced by perinatal administration of PCP in rats early in 
development and suggest that this may have implications for the hippocampal deficits seen in 
schizophrenia. 
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1. Introduction 
Phencyclidine, also known as angel dust or PCP, is both a potent non-competitive N-methyl-
D-aspartate (NMDA) receptor antagonist and an agonist for the dopamine D2 receptors1–3, 
but also binds with a lower affinity to opiate, nicotinic, and muscarinic cholinergic 
receptors4–7. Due to its effects on a multitude of important receptor targets known to be 
implicated in the schizophrenia pathology, PCP treatment in rodents has been used to model 
the glutamate hypofunction hypotheses and dopamine hyperfunction hypotheses of 
schizophrenia2,8. The use of PCP administration at postnatal days (PN)7, 9 and 11 has 
consistently been shown to induce hyperlocomotion, reduced prepulse inhibition and 
impaired social interactions in rodents9–11. The behaviors it induces in rodents in addition to 
the psychomimetic effects it has in humans, makes it a valid model for studying the 
development of schizophrenia12. 
The administration of PCP to rodents both induces neurotoxicity and causes major damage to 
all parts of the brain13,14. PCP administration at PN7, 9 and 11 has been repeatedly shown to 
result in an increase in neuronal degeneration in the frontal and cingulate cortex of rats15,16. 
Similarly, pro-apoptotic factors have been shown to be upregulated, and anti-apoptotic 
factors have been shown to be downregulated in rats treated perinatally with PCP compared 
to controls15. It is thought that elevated neuronal death during this perinatal period may be 
directly responsible for deficits in brain development, neuronal cytoarchitecture and 
plasticity; and thus may contribute to the appearance of some of the schizophrenia-like 
symptoms seen in these rats in adulthood. Furthermore, neurons are not the only brain cells 
that are affected by disruptions to NMDA receptor antagonists. Oligodendrocytes, like 
neurons are sensitive to PCP toxicity during development14, and considering their significant 
role in axonal connectivity and conduction, disruption to these processes during early 
neurodevelopment can have significant negative consequences, impacting on normal brain 
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development. Furthermore, oligodendrocytes play a major role in myelination processes, 
which have been shown to be altered after PCP treatment in rats13,14. We have previously 
shown in this rat model that myelin basic protein (MBP), a marker of mature 
oligodendrocytes is significantly reduced in early development by perinatal administration of 
PCP17. 
Here we study the effects of PCP treatment on Leucine-rich repeat and immunoglobulin 
domain-containing protein (Lingo-1) pathways, which are highly involved the regulation of 
myelination and neurite outgrowth processes, both integral processes involved in the 
pathophysiology of schizophrenia. Membrane bound signal-transducing protein Lingo-1 is 
expressed on both neurons and oligodendrocytes18. It signals alongside the Nogo receptor 
(NgR) co-receptor and either the p75 neurotrophin receptor or its functional homolog, TNF 
receptor orphan Y (TROY)19–21, both of which also play significant roles in apoptosis and cell 
survival pathways22,23. Altogether, the activation of this trimolecular receptor complex sets up 
a signaling cascade leading to growth cone collapse, preventing further axonal growth and 
inhibiting myelination18,24. Additional signaling co-factors such as With No Lysine K 
(WNK1)25, Myelin transcription factor 1 (Myt1) and its homolog Myt1-like (Myt1l) are 
known to be associated with Lingo-1 signaling due to a lack of p75 and TROY receptors on 
Lingo-1 expressing neurons26,27. Genetic associations with schizophrenia have been 
previously reported for the Myt1l gene in different populations28,29, and the knockdown of 
Myt1 has been shown to induce apoptosis30, strengthening the relevance of studying this 
Lingo-1 cofactor in a neurodevelopmental PCP induced model for schizophrenia. 
We have recently reported the first evidence of an alteration in Lingo-1 signaling pathways in 
a postmortem hippocampal human brain cohort for schizophrenia31. Considering the role of 
Lingo-1 signaling proteins in myelin related processes, the present study specifically focuses 
on Lingo-1 signaling protein alterations in the hippocampus due to activity-mediated myelin 
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growth being higher early in human life in hippocampal regions compared to cortical 
regions32. Considering that the perinatal administration of PCP to rodents is a well-
established developmental animal model for schizophrenia, we sought to investigate the 
effects of developmental PCP administration on levels of expression of Lingo-1 signaling 
proteins in the hippocampus, a critical region for early brain development. 
2. Methods 
2.1 Animals 
Timed pregnant Sprague Dawley rats were obtained at gestation day 14 from the Animal 
Resource Centre (Perth, WA, Australia). Rats were housed in environmentally controlled 
conditions at 22°C in a 12 hours on, 12 hours off light dark cycle with food and water access 
ad libitum. The day of birth was denoted postnatal day (PN)0, and the pups were sexed on 
PN7 when the litters were subsequently randomly assigned to PCP or saline groups. The 
female pups remained in the litters until weaning, however only male rats were used in this 
study. The pups were weaned at PN24-28, and were housed in pairs according to treatment. 
This study was approved by the Animal Ethics Committee at The University of Wollongong 
(AE13/01), and was conducted according to the guidelines of the Australian code of Practice 
for the Care and Use of Animals for Scientific Purposes, conforming to the International 
Guiding Principles for Biomedical Research Involving Animals. All efforts were made to 
minimize numbers of animals used and their suffering. 
2.2 Perinatal PCP Treatment 
Male Sprague Dawley rat pups were given a subcutaneous injection on PN7, 9 and 11; of 
PCP (10 mg/kg/day; Sigma, Castle Hill, NSW, Australia) or saline (0.9% NaCl at a volume 
of 1 ml/kg). Six rats from each treatment group (PCP and control) were sacrificed at three 
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different time-points, PN12 days, 5 weeks or 14 weeks of age, representing perinatal, 
adolescent and adult developmental stages respectively as described previously33,34. 
2.3 Rat Brain Tissue Preparation 
Rats were euthanized by carbon dioxide asphyxiation and decapitation at PN12, 5 weeks and 
14 weeks. Brains were extracted and the hippocampus was regionally dissected on ice with 
the aid of a standard rat brain atlas35. Immediately following dissection samples were snap 
frozen in liquid nitrogen and then stored at -80°C. Tissue was gently homogenized in a buffer 
(50 mM Tris pH 7.5, 50% glycerol), containing protease inhibitors (Sigma). Protein 
concentrations were determined by a spectrophotometer. All samples were diluted to a 
concentration of 2 μg/μL and stored at -80°C until required for immunoblotting, as previously 
detailed31. 
2.4 Immunoblotting 
Relative protein levels for all proteins of interest were determined by immunoblotting as 
previously described31. In short, proteins were resolved by SDS-PAGE, with a total of 10 µg 
protein loaded into each well of 4-12% pre-cast bis-Tris polyacrylamide gels (Bio-Rad). 
Proteins were subsequently transferred to polyvinylidene fluoride membranes (Bio-Rad). The 
polycolonal and monoclonal antibodies and their respective concentrations used to probe the 
membranes were as follows: anti-Lingo-1 (1:500; ab23631 Abcam), anti-NgR (1:500; 
ab26291 Abcam), anti-p75 (1:500; ab8874 Abcam), anti-TROY (1:200; ab12126 Abcam), 
anti-WNK1 (1:500; ab128858 Abcam), and anti-Myt1 (1:500; ab82844 Abcam). The Gel 
Logic 2200 Pro (Carestream Molecular Imaging; Rochester, NY, USA) was used to visualize 
and quantify the bands of interest. All samples were run in duplicate or triplicate, and were 
loaded in a randomized order with even numbers of PCP and control samples per time-point 
per gel to minimize the effects of gel-to-gel variability on the results. A pooled sample 
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combining aliquots from all 36 rats, was used as a positive control and was loaded onto each 
gel within the experiment to account for any gel-to-gel variability. Samples from each gel 
were then normalized to their respective pooled sample, and all bands were normalized to a 
β-actin (1:5000; MAB1501 Millipore) same lane loading control. Mean β-actin expression 
levels did not differ between PCP and control groups (p>0.05). All experiments and 
quantifications were performed blind to treatment and age group. 
2.5 Statistics 
As all data were normally distributed (Kolmogorov–Smirnov p>0.10), parametric testing was 
implemented. Two-way multivariate analyses of variance (MANOVA) followed by Tukey’s 
HSD post-hoc tests, were performed to assess interactions between treatment (PCP or 
control) and time-point (PN12, 5 weeks or 14 weeks). One-way analyses of variance 
(ANOVA) followed by Tukey’s HSD post-hoc tests, were used to assess for differences in 
protein expression across successive developmental time points within each treatment group. 
Unpaired two-tailed t-tests were also used at individual time-points to assess for differences 
in protein expression between PCP and control groups. The significance for all statistical tests 
was set to p<0.05. All data are expressed as mean±SD. 
3. Results 
3.1 Protein detection 
Lingo-1, NgR, p75, TROY, WNK1 and Myt1 proteins were abundantly expressed and 
detectable in the rat hippocampus. Western blot analyses of all proteins examined resulted in 
a single distinct band at the expected, previously reported molecular weights for each protein: 
Lingo-1 (83 kDa)36, NgR (51 kDa)37, p75 (75 kDa)38, TROY (46 kDa)39, WNK1 (250 kDa)31, 
and Myt1 (135 kDa)31 (Figure 1). 
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3.2 Hippocampal levels of p75, TROY and Myt1 protein expression are altered by 
perinatal administration of PCP in rats 
There was a highly significant age x treatment interaction on levels of both p75 and TROY 
protein expression in the treated rats (F2,30=9.39; p<0.001; and F2,30=7.69; p=0.002 
respectively). Post-hoc analyses reveal that at PN12, a significant decrease in p75 protein 
expression (-16%, p=0.011; Figure 1) was observed in perinatal PCP treated rats in 
comparison to control rats. Despite a decrease in levels of TROY, the functional homolog of 
p75, it was found not to be significantly different in PCP treated versus control rats at the 
PN12 time-point (-11%, p=0.061; Figure 1). Furthermore, a significant elevation in p75 
protein expression was observed in PCP treated compared to control rats at the 14 week time-
point (+22%, p=0.022; Figure 1). Similarly, levels of the p75 homolog TROY were also 
found to be significantly elevated in PCP treated compared to control rats at the 14 week 
time-point (+14.5%, p=0.021; Figure 1). While there was no considerable main effect of 
treatment on expression levels of p75 or its homolog TROY (F1,30=0.23; p=0.633; and 
F1,30=0.15; p=0.705 respectively), an extremely significant age effect on both p75 and TROY 
expression levels in the hippocampus of the treated rats was observed (F2,30=26.95; p<0.001; 
and F2,30=34.27; p<0.001 respectively; Supplementary Figures (SF) 1 and 2). Post-hoc 
analyses revealed that the age effect resulted in a significant increase in p75 (control: +25%, 
p=0.001, SF1; PCP: +47.5%, p<0.001, SF2) and TROY (control: +22.5%, p<0.001, SF1; 
PCP: +36%, p<0.001, SF2) when comparing the 5 week age groups to the PN12 age group. 
Furthermore, a significant elevation in both p75 (+49%, p<0.001, SF2) and TROY (+37%, 
p<0.001, SF2) expression was observed in the 14 week PCP treated rats compared to the 
PN12 PCP treated rats, however there was no significant alteration observed in the control 
rats when comparing the same age groups (SF1). Finally, there was a significant increase in 
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both p75 (+22%, p=0.008, SF1) and TROY (+15%, p=0.037, SF1) protein expression in 
control rats when comparing the 5 week to the 14 week group. 
Similar to the results of p75 and TROY, there was an extremely significant interaction 
between age and treatment on Myt1 levels in the hippocampus of the treated rats 
(F2,30=25.52; p<0.001). Post-hoc testing revealed that this interaction again results in a 
decrease at the PN12 (-18.5%, p<0.001; Figure 1) and an increase at the 14 week (+16%, 
p=0.014; Figure 1) time-points between the PCP treated rats and the controls. Furthermore, 
while there is no main treatment effect (F1,30=0.96; p=0.333), there was a considerable age 
effect on levels of Myt1 protein expression (F2,30=103.13; p<0.001). Post-hoc analyses 
showed that Myt1 was significantly altered when comparing the 5 week group to the PN12 
group (control: -15.5%, p=0.001, SF1; PCP +9%, p=0.016, SF2), when comparing the 14 
week group to the 5 week group (control: -43.5%, p<0.001, SF1; PCP -30%, p<0.001, SF2), 
as well as when comparing the 14 week group to the PN12 group (control: -69%, p<0.001, 
SF1; PCP -16%, p=0.001, SF2). 
3.3 Hippocampal levels of Lingo-1, NgR and WNK1 protein expression are unaltered by 
perinatal PCP treatment in rats 
There were no significant main effects of age (F2,30=3.01; p=0.064) or treatment (F1,30=0.36; 
p=0.555) on levels of Lingo-1 in the hippocampus of the treated rats; nor were there any 
significant interactions between the two factors (F2,30=1.41; p=0.259; Figure 1). Furthermore 
there were no significant interactions between age and treatment on levels of NgR in the 
treated rats (F2,30=0.54; p=0.589; Figure 1), nor an effect of treatment on NgR levels in the 
hippocampus (F1,30=0.14; p=0.710). However, an extremely significant age effect was 
observed in relation to NgR protein levels in the hippocampus of the treated rats (F2,30=18.69; 
p<0.001). Post-hoc analyses demonstrated that this age effect resulted in a considerable 
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increase in NgR expression levels in both control and PCP treated rats in both the 5 week 
(control: +55%, p=0.002, SF1; PCP: +48%, p=0.001, SF2) and 14 week (control: +37%, 
p=0.019, SF1; PCP: +49%, p=0.005, SF2) age groups compared to the PN12 age group, with 
the age effect being more highly significant in the PCP treated rats. 
As with Lingo-1 and NgR, there were no notable age x treatment interactions on the 
expression of hippocampal WNK1 protein levels in the treated rats (F2,30=0.39; p=0.683; 
Figure 1), nor an effect of treatment on WNK1 levels in the treated rats (F1,30=0.24; p=0.627). 
There was however a considerable age effect on WNK1 protein expression levels 
(F2,30=12.60; p<0.001). Similar to the expression pattern of NgR, post-hoc analyses revealed 
that the age effect resulted in a significant elevation of WNK1 expression levels in both 
control and PCP treated rats in both the 5 week (control: +29.5%, p=0.007, SF1; PCP: 
+46.5%, p=0.003, SF2) and 14 week (control: +34.5%, p=0.014, SF1; PCP: +49%, p=0.003, 
SF2) age groups compared to the PN12 age group, with the age effect again being more 
highly significant in the PCP treated rats. 
4. Discussion 
Here we provide the first study to investigate the developmental expression profile of 
hippocampal Lingo-1 signaling pathway proteins using a neurodevelopmental PCP model of 
schizophrenia. This study offers insight into the expression patterns of these proteins 
following the administration of an NMDA receptor antagonist at a critical period for brain 
development which is highly relevant in the context of the pathophysiology of schizophrenia. 
We have shown that the hippocampal expression of Lingo-1, NgR and WNK1 were not 
significantly altered by PCP treatment across the 3 tested developmental time-points, 
however the downstream signaling partners p75, TROY and Myt1 were decreased at PN12 
and increased at 14 weeks in PCP treated rats compared to their controls. Considering current 
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literature and the role that these three proteins play in apoptotic processes, our results suggest 
that these proteins may have implications in acute PCP induced neurotoxicity and thus may 
contribute to deficits in brain development, neuronal cytoarchitecture and plasticity of the 
brain early in the development of schizophrenia. 
4.1 Alterations of p75, TROY and Myt1 in a PCP induced neurodevelopmental animal 
model for schizophrenia 
Perinatal PCP treatment was found to significantly reduce p75 expression in the juvenile rats, 
and increase the expression of p75 in the adult PCP treated rats, with no change in p75 
expression in the adolescent rats (Figure 1). Reports on the expression of p75 neurotrophin 
receptor throughout development as well as in relation to schizophrenia in human 
postmortem brains, are limited and conflicting40, despite the p75 binding protein, brain-
derived neurotrophic factor (BDNF) being extensively studied41–43. In support of our 
findings, levels of p75 expression have been previously found to be significantly reduced in 
neonatal pups in a developmental rodent model used to study environmental influences in 
disorders such as schizophrenia44. It has been suggested that a reduction of p75 in early brain 
development could be quite detrimental due to the inability for neurotrophins, responsible for 
neurite outgrowth, to bind in a p75 dependent fashion, leading to an inability of axons to 
elongate throughout development45. Even though p75 expression is known to be associated 
with various apoptotic processes46,47, p75 neurotrophic factor also contributes to neuronal 
survival during development40,46. Tropomyosin receptor kinases (Trk), involved in p75-
induced neuronal survival processes40, are also implicated in NMDA receptor activation and 
regulation41.	 With regards to the non-specific antagonistic effects of PCP on the NMDA 
receptor, a decrease in the activity of TrkB receptor signaling has been shown in postnatal 
PCP treated rats48 (Figure 2). Due to the cross talk between p75 and Trk receptors, it was not 
surprising to see a significant reduction in the levels of p75 in the hippocampus of the 
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juvenile PCP treated rats compared to the controls in our study, which would lead to 
decreased survival of neurons early in development. As a follow-up to our study and to test 
this hypothesis, the levels of microtubule-associated protein 2 (MAP2; a commonly used 
neuronal marker, selectively labeling dendritic trees throughout the brain) were examined in 
the hippocampus of our perinatal treated rats (see supplementary methods, results and figure 
SF3). MAP2 levels were significantly decreased by 26.5% in the hippocampus of the juvenile 
PCP treated rats (p=0.008), supporting our hypothesis that a significant reduction in p75 in 
PCP treated rats would lead to an acute reduction in survival of neurons in the hippocampus 
of juvenile treated rats. 
Considering that p75 and TROY are functional homologs of one another, it seems fitting that 
we found a decrease of a similar magnitude in both p75 and TROY expression in the 
hippocampus of perinatal PCP treated rats, despite the reduction in TROY protein levels not 
reaching significance (p=0.061). We suggest that the very similar transient expression pattern 
of the homologous receptors p75 and TROY in PCP treated rats compared to controls 
throughout development may play a significant role in PCP induced neurotoxicity in juvenile 
rats in our neurodevelopmental animal model of schizophrenia. In support of this, it has been 
shown that postnatal PCP injections resulted in lower levels of phosphorylated ERK1/2 in the 
hippocampus of juvenile rats compared to controls49,50. Furthermore PCP treatment in 
organotypic brain slice culture from rats showed decreased phosphorylation levels of 
MEK1/2 and ERK1/2, both downstream signaling partners of p75 cell survival pathways, 
suggesting that PCP may induce cell death through the inhibition of the MEK/ERK/1/2 pro-
survival pathways51 (Figure 2). The expression pattern of p75 and TROY seems to recover 
over time, normalizing around adolescence as there are no significant differences in either 
p75 or TROY expression in the 5 week old rats (p>0.05). Furthermore, there are no 
significant alterations in MAP2 levels to indicate any significant alterations in neuronal 
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survival during adolescence (SF3). The levels of p75 and TROY are raised above control 
levels in the hippocampus of PCP treated rats by the time they reach adulthood at 14 weeks. 
This is supported by our previous finding in a postmortem human cohort showing an increase 
of both of these proteins in the hippocampus of adult schizophrenia brains compared to 
controls, despite p75 levels not reaching significance in our human study31. Considering there 
are no significant alterations in MAP2 levels between PCP treated and control rats at 
adulthood in the present study (SF3), this suggests that additional mechanisms may be 
involved in the regulation of these proteins in the adult schizophrenia brain which will need 
to be further investigated. 
In addition, Myt1 expression in our study was found to be significantly decreased by PCP 
administration in the hippocampus of the juvenile PN12 rats in comparison to control rats, 
but increased in the adult rats treated perinatally with PCP compared to controls. Knowing 
that Lingo-1 can directly suppress EGFR signaling leading to the inhibition and blockade of 
PI3-K/Akt signaling pathways31, and since we found Lingo-1 to be unaltered in the 
hippocampus in the perinatal PN12 PCP treated rats in the present study, we hypothesize that 
Akt signaling pathway inhibition by Lingo-1 would be reduced, thus resulting in increased 
levels of phosphorylated Akt signaling pathway proteins (Figure 2). Elevated Akt activation 
levels would lead to increased negative regulation of Myt1 intracellularly (Figure 2), thus 
resulting in lower Myt1 levels in the hippocampus of the juvenile PCP treated rats31. While 
we were unable to examine levels of phosphorylated Akt levels to support this hypothesis in 
the present study (due to an alternate method of sample preparation being required for the 
procedure), we were able to examine levels of total Akt protein (see supplementary methods, 
results and figure SF3). We found that there were no significant alterations in total Akt levels 
in any of the tested age groups in PCP rats compared to controls (p>0.05). This result has 
been previously shown by our research group34; furthermore in the same cohort of rats our 
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group has demonstrated that perinatal PCP treatment at PN7, 9 and 11 results in increased 
levels of phosphorylated Akt at both juvenile and adolescent stages of life in the 
hippocampus34, supporting our hypothesis for increased levels of activated Akt in this model 
leading to the reduced levels of Myt1 protein observed in juvenile rats in the present study. In 
further support of this, Xia and Johnson (2009) have also demonstrated that phosphorylated 
Akt levels were increased in adolescent rats that were treated with PCP on postnatal days 7, 9 
and 11 compared to rats treated with saline49,50. Along with the decreased levels of Myt1 
protein in PCP treated rats at the juvenile period compared to their controls, we have reported 
in a previous study17 the levels of MBP as a marker of mature oligodendrocytes in this animal 
model, and have shown that MBP is significantly reduced in PN12 animals following 
perinatal PCP administration, suggesting an acute alteration of glia by PCP treatment.  
In addition, elevated levels of activated Akt may contribute to an increased expression of the 
apoptotic marker p53, responsible for regulating another apoptotic marker bcl-2-associated X 
protein (or BAX) which has previously been reported to be increased after PCP 
administration at PN7, 9 and 1152. To test this hypothesis as a follow-up to our study, we 
examined levels of BAX protein in our rats (see supplementary methods, results and figure 
SF3) and found a significant 26% increase in BAX expression in the juvenile PCP treated rats 
compared to controls (p=0.03). Since p53 and BAX are regulated by Mouse double minute 2 
homolog (MDM2)53,54, we would also expect to see an increase in MDM2 expression in the 
juvenile rats due to a rise in the levels of p53 and following perinatal PCP administration 
requiring a large recruitment of MDM2 for its ubiquitination (Figure 2). 
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4.2 Hippocampal expression of Lingo-1 and its signaling proteins NgR, and WNK1 are 
unaltered following perinatal PCP treatment 
Hippocampal levels of Lingo-1 and NgR both presented with similar transient expression 
patterns throughout development in both the control and PCP treated rats, despite neither of 
the proteins being significantly altered by PCP treatment at any of the three developmental 
time-points (Figure 1); both proteins were increased during adolescence (SF1 and SF2). 
Considering the extensive synaptic changes that occur during adolescence (reductions in 
dendritic arborization, and pruning of synapses)55, it was not surprising to detect higher levels 
of these important negative regulators of neurite outgrowth at this critical period of 
development in the control rats. Although slightly reduced following PCP treatment, levels of 
both proteins were still elevated in the adolescent rats above that which is seen in the juvenile 
rats, and remained elevated into adulthood (SF2). 
Similarly, levels of WNK1 expression were gradually increased with age in the hippocampus 
of both the control and PCP treated rats. Our finding is consistent with a recent observation 
demonstrating elevated WNK1 expression in the hippocampus of adult compared to juvenile 
PN10 mouse brains56. Furthermore, WNK1 levels were also found to be unaltered in all age 
groups of the present study when comparing PCP treated rats to control rats; similar to the 
expression patterns of Lingo-1 and NgR in this study. Considering that WNK1 is a direct 
binding partner of Lingo-1 and since WNK1 directly regulates NgR31, it seems appropriate 
that we observed these similar profiles of expression for Lingo-1, NgR and WNK1 following 
the perinatal PCP treatment. 
5. Conclusion 
In review, we report for the first time alterations in Lingo-1 signaling pathway proteins, 
particularly those which have significant roles in neuronal survival and apoptotic processes, 
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in the hippocampus of rats from a neurodevelopmental PCP model of schizophrenia. We have 
shown an altered developmental trajectory of a number of these signaling proteins, in 
particular at perinatal and adult stages of life. Our results in concert with current literature, 
suggest that components of the Lingo-1 signaling pathways may be involved in the acute 
neurotoxicity induced by perinatal administration of PCP in rats and suggest that this may 
have implications for the hippocampal deficits seen in schizophrenia, however further studies 
will be required to fully elucidate the molecular mechanisms involved. 
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Figure Legends 
Figure 1: Relative levels of protein expression in the hippocampus of phencyclidine (PCP) 
treated rats compared to controls (n=6 per treatment per time-point). * p<0.05, ** p<0.01 
and *** p<0.001. 
Figure 2: Proposed schematic representation of the acute effects of phencyclidine (PCP) 
administration resulting in activation of cell death pathways. A reduction in p75 protein 
expression was observed in the present study, and TrkB receptor signaling activity has 
previously been shown to be reduced in postnatal PCP treated rats. Together these proteins 
are normally involved in p75-induced neuronal survival processes1; a reduction in protein or 
phosphorylation levels can lead to a reduction in MEK1/2 and ERK1/2 activation. Reduced 
phosphorylation of the MEK1/2 ERK1/2 pathways has been shown to result from PCP 
treatment2. Lingo-1 can directly inhibit EGFR leading to the inhibition of PI3-K/Akt 
signaling pathways3; since Lingo-1 was unaltered in the present study, we suggest that Lingo-
1 induced inhibition of Akt signaling pathways would be reduced and result in increased Akt 
signaling, causing increased negative regulation of Myt1 intracellularly3. Our group has 
previously shown that perinatal administration of PCP results in an acute increase in 
phosphorylated Akt levels in the hippocampus of rats4. Furthermore, activation of apoptotic 
signaling cascades via Akt leads to an increase in p53 and Bax5 (also shown by the present 
study), mainly regulated by MDM26,7. An immediate rise in the levels of p53 following 
perinatal PCP administration would require a large recruitment of MDM2 for its 
ubiquitination. 
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Supplementary Methods 
Immunoblotting of neuronal marker microtubule-associated protein 2 (MAP2), total Akt, and apoptotic 
marker Bcl-2-associated X protein (BAX) in the hippocampus of PCP treated and control rats 
Relative protein expression for MAP2, total Akt and BAX levels were determined by immunoblotting 
conducted according to the protocol described in the main methods of this study; the only modification from 
the protocol described in manuscript being the primary antibodies used. The primary antibodies and 
concentrations used to perform these additional experiments were as follows: anti MAP2 (1:1000; M4403; 
Sigma), total Akt (1:500; sc-8312; Santa Cruz) and BAX (1:500; ab7977; Abcam). 
 
Supplementary Results 
MAP2. There was a significant age x treatment interaction on MAP2 protein expression in the treated rats 
(F2,29=3.87; p<0.001). Post-hoc analyses reveal that there was a 26.5% decrease in MAP2 protein expression 
in the PN12 PCP treated rats compared to control rats (p=0.008; SF3). While there was no main effect of 
treatment on expression levels of MAP2 (F1,29=0.07; p=0.789), there was an extremely significant age effect 
on MAP2 expression levels in the hippocampus of the treated rats (F2,29=35.23; p<0.001). Post-hoc analyses 
showed that MAP2 protein expression was 41% and 44% higher in the 5 week and 14 week control groups 
respectively compared to the PN12 group, similarly MAP2 protein expression was increased by 57.5% and 
61.5% respectively in the 5 week and 14 week PCP treated groups compared to the PN12 group 
(0.001<p<0.05; SF4). 
Akt. As expected, there were no significant interactions between age and treatment on total Akt levels in the 
hippocampus of the treated rats (F2,30=0.24; p=0.791; SF3); nor was there a significant main effect of 
treatment (F1,30=2.08; p=0.159). There was however a highly significant main effect of age on total Akt 
levels (F2,30=22.03; p<0.001). Post-hoc analyses revealed that total Akt protein expression levels were 16% 
and 28.5% lower in the 5 week and 14 week control age groups respectively compared to the PN12 age 
group, and were 29.5% lower in the 14 week PCP treated group compared to the PN12 PCP group 
(0.001<p<0.05; SF4). 
 
Bax. There were no significant interactions between age and treatment on levels of BAX protein in the 
treated rats (F2,29=1.042; p=0.366); however there was a significant effect of treatment on BAX levels in the 
hippocampus (F1,29=6.706; p=0.014), with post-hoc analyses revealing that the treatment effect was 
observed only in the PN12 age group, with a 26% increase in BAX protein in the hippocampus of PN12 
PCP treated rats compared to controls (p=0.03; SF3). There was an extremely significant age effect in 
relation to BAX protein levels in the hippocampus of the treated rats (F2,29=39.71; p<0.001). Post-hoc 
analyses revealed that BAX protein levels were 29% higher in 5 week old control rats, 42% higher in 14 
week old control rats compared to PN12 rats, and 19% higher in 14 week old control rats compared to 5 
week old rats (0.001<p<0.01). Furthermore BAX levels were found to be 30% higher in 14 week old PCP 
treated rats compared to PN12 PCP treated rats (p<0.001). 
 
Supplementary Figures 
 
SF1: Developmental profile of Lingo-1, NgR, p75, TROY, WNK1 and Myt1 protein expression in the hippocampus of control rats at PN12, 5 week, and 14 
week time-points (n = 6 per time-point). *p<0.05, **p<0.01, and ***p<0.001. 
 
 
 
SF2: Developmental profile of Lingo-1, NgR, p75, TROY, WNK1 and Myt1 protein expression in the hippocampus of phencyclidine-treated rats at PN12, 5 
week, and 14 week time-points (n = 6 per time-point). *p<0.05, **p<0.01 and ***p<0.001.
 
 
 
SF3: Representative immunoblots and relative levels of MAP2, total Akt and BAX protein expression in the 
hippocampus of phencyclidine (PCP) treated rats compared to controls (n = 6 per treatment per time-point).        
*p<0.05, and **p<0.01.
 
 
SF4: Developmental profile of MAP2, total Akt and BAX protein expression in the hippocampus of control and phencyclidine (PCP) treated rats at PN12, 5 
week, and 14 week time-points (n = 6 per treatment per time-point). *p<0.05, **p<0.01, and ***p<0.001. 
